Observation vs. Treatment in PLGG: Functional Outcomes, NF1 Status, and Shared Decision-Making

In this segment, Dr. Margol and Dr. Chintagumpala tackle one of the most complex decisions in pediatric neuro-oncology: when to observe versus treat a pediatric low-grade glioma (PLGG).

Deciding whether and when to treat PLGG is, paradoxically, among the hardest decisions in the field—because the goal is not to eliminate the tumor but to preserve function. The guiding principle is to "treat the patient, not the picture": if a child looks well clinically, a growing tumor on MRI may not warrant intervention. Two key questions drive the decision: Could therapy improve existing symptoms, or could withholding therapy allow symptoms to worsen? Vision loss in optic pathway gliomas is a critical trigger, as lost vision is very difficult to regain. Sustained radiographic growth threatening future function also prompts treatment, but decisions are driven primarily by functional outcomes rather than imaging alone.

NF1 status adds an important nuance: clinicians are more likely to observe NF1-associated tumors and wait for documented vision changes before treating, whereas in non-NF1 patients, radiographic progression may precede vision loss by a lag period, prompting earlier intervention. Psychosocial factors and shared decision-making with families are central to every plan, making it difficult for outside observers to understand why one child's treatment differs from another's.

In the next episode, "MRI Interpretation, Hemorrhage, and Multidisciplinary Monitoring in PLGG," the panel discusses how to interpret MRI changes, the significance of intratumoral hemorrhage, and the essential role of multidisciplinary care teams.